MY-COMP, an inhibitor of the transcriptional activity of YAP-B-MYB, identifies NEK2 as a novel mediator of YAP oncogenesis in uveal melanoma cells [RNA-seq]
RNA-seq (gene expression) · human · 21 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 21 samples: 7 conditions, mostly in triplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Inhibition of the YAP-MMB interaction and targeting NEK2 as potential therapeutic strategies for YAP-driven cancersOncogene · 2024
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE227973_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA947601 and SRA study SRP428755. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 21 samples.
How we read this: 7 replicated groups read from 21 sample titles; they account for 21 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM7111612 RNAseq_92_1_siCtrl_rep1 RNAseq_92_1_siCtrl
- GSM7111613 RNAseq_92_1_siCtrl_rep2 RNAseq_92_1_siCtrl
- GSM7111614 RNAseq_92_1_siCtrl_rep3 RNAseq_92_1_siCtrl
- GSM7111615 RNAseq_92_1_siYAP_rep1 RNAseq_92_1_siYAP
- GSM7111616 RNAseq_92_1_siYAP_rep2 RNAseq_92_1_siYAP
- GSM7111617 RNAseq_92_1_siYAP_rep3 RNAseq_92_1_siYAP
- GSM7111618 RNAseq_92_1_MY_COMP_rep1 RNAseq_92_1_MY_COMP
- GSM7111619 RNAseq_92_1_MY_COMP_rep2 RNAseq_92_1_MY_COMP
- GSM7111620 RNAseq_92_1_MY_COMP_rep3 RNAseq_92_1_MY_COMP
- GSM7111621 RNAseq_MCF10A_noDox_noOHT_rep1 RNAseq_MCF10A_noDox_noO…
- GSM7111622 RNAseq_MCF10A_noDox_noOHT_rep2 RNAseq_MCF10A_noDox_noO…
- GSM7111623 RNAseq_MCF10A_noDox_noOHT_rep3 RNAseq_MCF10A_noDox_noO…
- GSM7111624 RNAseq_MCF10A_noDox_withOHT_rep1 RNAseq_MCF10A_noDox_wit…
- GSM7111625 RNAseq_MCF10A_noDox_withOHT_rep2 RNAseq_MCF10A_noDox_wit…
- GSM7111626 RNAseq_MCF10A_noDox_withOHT_rep3 RNAseq_MCF10A_noDox_wit…
- GSM7111627 RNAseq_MCF10A_withDox_noOHT_rep1 RNAseq_MCF10A_withDox_n…
- GSM7111628 RNAseq_MCF10A_withDox_noOHT_rep2 RNAseq_MCF10A_withDox_n…
- GSM7111629 RNAseq_MCF10A_withDox_noOHT_rep3 RNAseq_MCF10A_withDox_n…
- GSM7111630 RNAseq_MCF10A_withDox_withOHT_rep1 RNAseq_MCF10A_withDox_w…
- GSM7111631 RNAseq_MCF10A_withDox_withOHT_rep2 RNAseq_MCF10A_withDox_w…
- GSM7111632 RNAseq_MCF10A_withDox_withOHT_rep3 RNAseq_MCF10A_withDox_w…
- GSE227974 MY-COMP, an inhibitor of the transcriptional activity of YAP-B-MYB, identifies NEK2 as a novel mediator of YAP oncogenesis in uveal melanoma cells 29 samples shares my-comp, nek2, yap, oncogenesis, identifies, inhibitor, yap-b-myb, activity
- GSE305227 Covalent pan-TEAD inhibitors block YAP activity and demonstrate brain penetrance in Hippo-dependent cancer models [Quant-seq] 149 samples shares yap, inhibitor, activity
- GSE305224 Covalent pan-TEAD inhibitors block YAP activity and demonstrate brain penetrance in Hippo-dependent cancer models [RNA-seq] 120 samples shares yap, inhibitor, activity
- GSE305254 Covalent pan-TEAD inhibitors block YAP activity and demonstrate brain penetrance in Hippo-dependent cancer models 299 samples shares yap, inhibitor, activity
- GSE330305 Covalent pan-TEAD inhibitors block YAP activity and demonstrate brain penetrance in Hippo-dependent cancer models [ATAC-seq] 30 samples shares yap, inhibitor, activity
- GSE249903 Activation of hepatocyte growth factor (HGF)/MET signaling as a mechanism of acquired resistance to a novel YAP1/TEAD small molecule inhibitor. 49 samples shares yap, inhibitor
- GSE335516 CDK7 inhibition suppresses Hippo-YAP signaling to reverse CDK4/6 inhibitor resistance in hormone receptor-positive breast cancer 18 samples shares yap, inhibitor
- GSE229195 Synergism of FAK and ROS1 inhibitors in the treatment of CDH1-deficient cancers mediated by FAK-YAP-TRX signaling 12 samples shares yap, inhibitor
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.